From 23-25 October, the 29th Alzheimer Europe Conference “Making valuable connections” brought together over 950 participants from 46 countries in The Hague (Netherlands). The event involved 287 speakers and 241 poster presentations.

Prior to the opening ceremony, the Neuronet (Efficiently Networking European Neurodegeneration Research) project, a coordination and support action funded by the Innovative Medicines Initiative,  convened the second meeting of its Scientific Coordination Board. José Luis Molinuevo from the Barcelona Beta Brain Research Center (BBRC) represented AMYPAD at the Neuronet Scientific Coordination Board Meeting in The Hague.

This year, Neuronet held four parallel sessions as part of the Alzheimer Europe conference showcasing projects that are working to improve our understanding, diagnosis and treatment of neurodegenerative disease. The fourth Neuronet session “Diagnosis, patient engagement and trials” was chaired by José Luis Molinuevo. We were pleased that José Luis Molinuevo presented AMYPAD and how the project can help providing answers to the value of amyloid PET in clinic and in the context of preventive trials. He highlighted the design of the AMYPAD Diagnostic and Prognostic studies and their progress. We were thrilled to also hear about the EPAD project presented by Craig Ritchie. During this session, Mercè Boada and Dag Aarsland presented respectively the MOPEAD and the RADAR-AD projects.

Mark the dates of the next Alzheimer Europe Conference “Building bridges” in your calendar. The event will take place in Bucharest (Romania) from 20 to 22 October 2020.